MC38-hIL1β
品系基本信息
*使用本品系发表的文献需注明: MC38-hIL1β cell line (Cat. NO. NMC-250201) was purchased from Shanghai Model Organisms Center, Inc..
验证数据
Fig1. The anti-hIL1β mAb Canakinumab alone or in combination with Tecentriq significantly inhibited the growth of MC38-hIL1β tumors in C57mice, demonstrating that this model is suitable for evaluating the in vivo efficacy of anti-hIL1β mAb alone and in combination with PD-1/PD-L1 antibodies.
Fig. 2 Blinatumomab injections were repeated daily for 5 days and immune cells in the PB of mice after therapy were measured by flow cytometry.
你也可能感兴趣
Tamoxifen诱导Cre-ERT2小鼠 使用指南
Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。
查看
